sameAs
Antonella BrunelloAngela GrassiStefano IndraccoloCarlo Riccardo RossiDebora CarpaneseAntonio RosatoGiuseppe LombardiJacopo PigozzoFotios LoupakisLaura EvangelistaAnna Rita CervinoFrancesca BattaglinMarta SchirripaMaria Luisa CalabròElisabetta CavedonE RumiatoRita AlfieriDaniele NucciAlessandro SinigagliaFrancesco CiccareseVittorina ZagonelSara ValpioneSilvia GiuncoA FabozziAntonio SommarivaL WeisCecilia GarofaloLisa ElefantiMaria Chiara ScainiElena FasanaroFederica VianelloMaria Vittoria DieciValentina GuarneriCamilla StagniElisa TaschinJessica MenisSamantha SerpentiniAnnalisa MartinesCinzia CandiottoElisabetta Zulato
P108
FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon CancerNGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With PemetrexedPhase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPMThe EPIC Trial The Elderly Patient Individualized Chemotherapy TrialCAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomasClinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
P6153
Q37829149-EA6DB069-7921-4005-9847-7C739E08FC59Q38319933-054970C9-4633-4522-9310-465DFF96DBA2Q39186456-50C41BC9-F553-48AC-A474-42BC1B566CDAQ40058555-91576BE7-28FE-4254-965B-A3134F9429F4Q40676113-74ED7249-B75A-4E58-A666-A217ED9FB0B8Q40676155-0D16F282-1F0B-4BD7-975E-4AF05B3DF475Q42370038-94EF3D84-4335-48C1-9270-C1EDEB7711A1Q46015009-6707589C-F2DB-428A-B152-6B8F609EEA84Q46107172-E4CA97DF-E294-4ECD-B67C-3AC2E8A8B939Q52983502-49CBF63C-E474-478C-AC67-A7F155A0340AQ53065838-321CD740-8A0A-4051-AEC9-ED75DC27BF12Q54963247-1A6876E5-CB08-4E7A-B10F-6B06B8591C8EQ54963251-2AECA9E0-550D-40B7-8D83-36748F399519Q55221715-9F569C53-EA35-40E8-ACD1-5CA89E736645Q55728873-1491406F-7EA4-44B1-A05C-22476894DEE9Q55755027-646893A9-DD50-4A6A-AAF3-98782FB04FC8Q55755145-E8790080-BD0A-4832-98A6-B21D54823AB8Q56376914-3CE0E476-2D1C-4B3F-A9F6-4E02C3EF379FQ56384218-470F32FD-305F-4166-ACC1-C9F058933685Q56836102-C763DE2C-B9BB-4A71-80BD-122633107857Q56836102-C7BB1F37-43D4-4225-80A7-D72108DA81C6Q56925944-B329DF21-1712-48F5-8C0A-DB38CCB5DB83Q56925944-B8801D25-1148-4DBD-8424-0398BA8F31E9Q57004141-D34843CA-04AF-4B7C-BE36-1A310F6F4CA4Q57004158-C5BE1411-F4BF-4A00-A74B-41FCE5469A8DQ57013793-BC8C3D02-4581-463E-BE58-3FA6B742872EQ57025394-AF365B8B-6D7B-410E-9009-8A87BCCC73DDQ57048170-17973A5F-5501-49D6-A2BA-E3B9028A09CDQ57079720-07A41C87-32ED-4983-B1E1-CEF7B35457FCQ57079858-CC7B0CA6-8548-47A8-9648-D7342270B7A8Q57079861-F21B5FE1-5F8C-48EF-8CCE-0A0D23C2419AQ57362609-3D5BAB0A-F46B-45B7-8A94-BB1AC19C3FD7Q57416836-34BAFFA4-8158-4494-8350-B0588FA75AD6Q57656975-74D4D582-2115-4290-B9A4-19D8D15BF8ADQ58283362-35879C46-87E5-4773-B181-D24228CE1FE9Q58386644-FBA000FE-D4EF-4731-8577-7F51819DA0EEQ58415003-C81BA42E-2CAF-4E6E-9135-721D77AF363BQ58462345-FFAA08F5-D479-4ED5-AD1D-ACEBE9D27530Q58492147-D5FC5905-9447-4355-84B5-831C3E8D676BQ58659120-949FA518-7239-4B1D-B45D-7831971E070B
P108
description
healthcare organization in Padua, Italy
@en
name
Istituto Oncologico Veneto
@en
Istituto Oncologico Veneto
@it
type
label
Istituto Oncologico Veneto
@en
Istituto Oncologico Veneto
@it
altLabel
IOV
@en
Veneto Institute of Oncology
@en
prefLabel
Istituto Oncologico Veneto
@en
Istituto Oncologico Veneto
@it
P131
P17
P213
0000 0004 1808 1697
P2427
grid.419546.b
P3500
P571
2005-01-01T00:00:00Z
P625
Point (11.893256 45.402391)